News | January 31, 2026
Glenmark reports robust Q3 FY26 performance, revenues surge 15% YoY
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
With its unique combination of AI, population-specific research, and international collaboration, BioMed X’s Barbados project represents a bold new frontier in precision medicine for diabetes and kidney disease
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
A PhD in Pharmaceutical Sciences, Dr Singh has led global regulatory audits, product validations, and quality systems spanning therapeutic formulations, dietary supplements, and functional foods
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
The partnership initially will focus on cardiovascular and kidney diseases
The capital was raised via multiple-tenure non-convertible debentures (NCDs) and commercial papers
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
Subscribe To Our Newsletter & Stay Updated
